Document is current
Any future updates will be listed below
-
Authors
Kumaraswamy, Anbarasu
Hu, Ya-Mei
Yates, Joel A.
Zhang, Chao
Rodansky, Eva
Khokhani, Dhruv
Flores, Diana
Duan, Zhi
Zhang, Yi
Tabatabaei, Shaadi
Slottke, Rachel
Ye, Shangyuan
Lara, Primo
Foye, Adam
Ryan, Charles J.
Quigley, David A.
Huang, Jiaoti
Aggarwal, Rahul
Reiter, Robert E.
Wicha, Max S.
Beer, Tomasz M.
Rettig, Matthew
Gleave, Martin
Evans, Christopher P.
Witte, Owen N.
Stuart, Joshua M.
Thomas, George V.
Feng, Felix Y.
Small, Eric J.
Xia, Zheng
Alumkal, Joshi J.
-
Funding
Funding for this research was provided by:
National Institutes of Health (T90 DE030859)
Stand Up to Cancer-Prostate Cancer Foundation (PCF) Prostate Dream Team Translational Cancer Research Grant (SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409, SU2C-AACR-DT0409)
National Institute of General Medical Sciences (R01GM147365)
U.S. Department of Defense (W81XWH2110539)
Prostate Cancer Foundation Challenge Award
Joint Institute for Cancer Research Award
National Cancer Institute (R01CA251245, R01CA282005, P50 CA186786, P30CA046592,R01CA291986)
- License Information
-
More Information
Article History
Received: 29 January 2025
Accepted: 7 June 2025
First Online: 7 July 2025
Competing interests
: J.H. is a consultant for or owns shares in the following companies: Artera, Kingmed Diagnostics, MoreHealth, OptraScan, York Biotechnology, Chimigen Bio, Pfizer, and Sisu Pharma. T.M. Beer reports employment by Exact Sciences; stock and other ownership interests in Exact Sciences, Salarius Pharmaceuticals, Osteologic, and Osheru; and consulting fees from Arvinas, AstraZeneca, Sanofi, and GlaxoSmithKline. His institution has also received research funding from Alliance Foundation Trials, Astellas, Freenome, GRAIL Inc., Bayer, Adela, and Delfi Diagnostics. M. Rettig has received consulting fees from Inmune Bio and Janssen, research funding from Merck, Amgen, and Progenics, and speaker fees from Janssen and Bayer. O.N. Witte reports consulting, equity, and/or board relationships with Trethera Corporation, Kronos Biosciences, Sofie Biosciences, Breakthrough Properties, Vida Ventures, Nammi Therapeutics, Two River, Iconovir, Appia BioSciences, Neogene Therapeutics, 76Bio, and Allogene Therapeutics. None of these companies contributed to or directed any of the research reported in this article. J.J. Alumkal has received consulting fees from Fortis Therapeutics and ORIC Pharmaceuticals, and research support to his institution from Beactica and Zenith Epigenetics outside of the submitted work. His institution has also received research support from Astellas for the ’Genetic and Molecular Mechanisms in Assessing Response in Patients with Prostate Cancer Receiving Enzalutamide’ clinical trial and a National Comprehensive Cancer Network (NCCN)/Astellas Pharma Global Development, Inc./Pfizer, Inc. research award that supported the analyses in this report. The remaining authors declare no conflicts of interest.
